Cigna Group

CI remains in a Stage 3 distribution regime with key EMAs and the 50 DMA acting as resistance, reinforcing a medium-term bearish bias. Price repeatedly fails to sustain above the 9/21 EMAs and 50 DMA, and short-term momentum is negative as RSI sits below midline and price rejects at dynamic resistances. The Bullish Pivot Point did not lead to lasting upside, signaling continued supply dominance. Execution should be active on rallies into the EMAs or near the 50 DMA, selling now into these resistance zones.

• ↑Q1 net revenue $68.5B (+9% YoY) with adjusted EPS $7.79 (+16%).
• ↑Raised 2026 adjusted EPS guidance to ≥$30.35, reflecting strong execution.
• ↓Negative profitability factors suggest near-term margin compression.